Eli Lilly & Co. vs. Nektar Therapeutics
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| LLY | NKTR | |
|---|---|---|
| Market Cap | $1.09 trillion | $2.57 billion |
| Revenue (TTM) | — | $55.63 million |
| Net Income (TTM) | — | $-158,098,000 |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | NKTR | |
|---|---|---|
| Price / Book | — | 4.46 |
| Price / Sales | — | 46.17 |
LLY and NKTR split the valuation factors evenly.
Profitability
| LLY | NKTR | |
|---|---|---|
| Net Margin | — | -284.18% |
| Return on Equity | — | -27.44% |
LLY and NKTR split the profitability factors evenly.
Risk & Sentiment
| LLY | NKTR | |
|---|---|---|
| Short Interest | 1.29% | 31.57% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, NKTR overview, NKTR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.